Carbapenem Market Size & Share – Trends Report, 2032

Carbapenem Market - By Drug Class (Meropenem, Imipenem, Ertapenem, Doripenem), Application (Urinary Tract, Bloodstream, & Intra-Abdominal Infections, Bacterial Meningitis), Distribution Channel – Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of antibiotic-resistant infections

3.2.1.2&nbsp;&nbsp;&nbsp; High R&amp;D investments in clinical research

3.2.1.3&nbsp;&nbsp;&nbsp; Growing incidence of hospital-acquired infections

3.2.1.4&nbsp;&nbsp;&nbsp; Increased awareness and diagnostic advancements

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of production of carbapenem-based antibiotics

3.2.2.2&nbsp;&nbsp;&nbsp; Side effects and safety concerns

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Technological landscape

3.5.1&nbsp;&nbsp;&nbsp; Core technologies

3.5.2&nbsp;&nbsp;&nbsp; Adjacent technologies

3.6&nbsp;&nbsp;&nbsp; Pricing analysis, 2023

3.6.1&nbsp;&nbsp;&nbsp; By region

3.6.2&nbsp;&nbsp;&nbsp; By key player

3.7&nbsp;&nbsp;&nbsp; Future market trends

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Class, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Meropenem

5.3&nbsp;&nbsp;&nbsp; Imipenem

5.4&nbsp;&nbsp;&nbsp; Ertapenem

5.5&nbsp;&nbsp;&nbsp; Doripenem

5.6&nbsp;&nbsp;&nbsp; Other drug classes

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Urinary tract infections

6.3&nbsp;&nbsp;&nbsp; Bloodstream infections

6.4&nbsp;&nbsp;&nbsp; Intra-abdominal infections

6.5&nbsp;&nbsp;&nbsp; Bacterial meningitis

6.6&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

7.3&nbsp;&nbsp;&nbsp; Retail pharmacies

7.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; AstraZeneca PLC

9.2&nbsp;&nbsp;&nbsp; Aurobindo Pharma

9.3&nbsp;&nbsp;&nbsp; Daewoong Pharmaceuticals Co., Ltd.

9.4&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

9.5&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

9.6&nbsp;&nbsp;&nbsp; Kopran Limited

9.7&nbsp;&nbsp;&nbsp; Lupin Limited

9.8&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

9.9&nbsp;&nbsp;&nbsp; Novartis AG

9.10&nbsp;&nbsp;&nbsp; Pfizer Inc.

9.11&nbsp;&nbsp;&nbsp; Shenzhen Haibin Pharmaceutical Co. Ltd.

9.12&nbsp;&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd.

9.13&nbsp;&nbsp;&nbsp; The Menarini Group

9.14&nbsp;&nbsp;&nbsp; Venus Remedies Ltd.

9.15&nbsp;&nbsp;&nbsp; Viatris Inc.

&nbsp;&nbsp;&nbsp;

Carbapenem Market

Get a free sample of this report